实践中的循证政策：类癌综合征腹泻的管理
Evidence-Based Policy in Practice: Management of Carcinoid Syndrome Diarrhea.
作者信息
Cook Richard, Hendifar Andrew E
出版信息
P T. 2019 Jul;44(7):424-427.
Abstract
Carcinoid syndrome causes substantial morbidity and reduces quality of life and survival. In a recent clinical trial, 97% of patients reported bowel movement-related issues, abdominal pain, flushing, and low energy. Combining somatostatin analogs with elotristat ethyl provides a new option for managing refractory CS symptoms. Health care providers should consider strategies that take advantage of approved dosing for patients with CS-related diarrhea.
摘要
类癌综合征会导致严重的发病率，并降低生活质量和生存率。在最近的一项临床试验中，97%的患者报告了与排便相关的问题、腹痛、潮红和精力不足。将生长抑素类似物与艾托司他乙酯联合使用为治疗难治性类癌综合征症状提供了一种新选择。医疗保健提供者应考虑利用已批准的剂量策略来治疗类癌综合征相关腹泻患者。
相似文献
1
Evidence-Based Policy in Practice: Management of Carcinoid Syndrome Diarrhea.实践中的循证政策：类癌综合征腹泻的管理
P T. 2019 Jul;44(7):424-427.
2
TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.远程医疗：在真实世界中，依维莫司乙酯起始治疗后患者报告类癌综合征症状改善。
Oncologist. 2019 Nov;24(11):1446-1452. doi: 10.1634/theoncologist.2018-0921. Epub 2019 Jun 12.
3
Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.在五项针对类癌综合征患者的临床研究中观察到托利司他乙酯的长期安全性。
Oncologist. 2019 Aug;24(8):e662-e670. doi: 10.1634/theoncologist.2018-0236. Epub 2019 Jan 16.
4
Developments in the treatment of carcinoid syndrome - impact of telotristat.类癌综合征治疗的进展——替洛曲汀的影响
Ther Clin Risk Manag. 2018 Feb 20;14:323-329. doi: 10.2147/TCRM.S126143. eCollection 2018.
5
Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.乙基替洛曲坦：在治疗高分化转移性神经内分泌肿瘤和类癌综合征腹泻方面的原理验证及首个口服药物。
Cancer Chemother Pharmacol. 2017 Dec;80(6):1055-1062. doi: 10.1007/s00280-017-3462-y. Epub 2017 Oct 19.
6
Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea.替洛利司他乙酯：一种用于治疗类癌综合征腹泻的新型药物。
Future Oncol. 2018 May;14(12):1155-1164. doi: 10.2217/fon-2017-0340. Epub 2018 Jan 19.
7
A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome.在未控制的类癌综合征患者中添加替洛利司他乙酯治疗的标准治疗的预算影响模型。
Pharmacoeconomics. 2020 Jun;38(6):607-618. doi: 10.1007/s40273-020-00896-5.
8
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.托利司他特乙酯在类癌综合征中的应用：TELECAST 三期临床试验的安全性和疗效。
Endocr Relat Cancer. 2018 Mar;25(3):309-322. doi: 10.1530/ERC-17-0455. Epub 2018 Jan 12.
9
Telotristat ethyl: a new option for the management of carcinoid syndrome.乙基替洛曲坦：类癌综合征管理的新选择。
Expert Opin Pharmacother. 2016 Dec;17(18):2487-2498. doi: 10.1080/14656566.2016.1254191. Epub 2016 Nov 16.
10
Telotristat ethyl for the treatment of carcinoid syndrome diarrhea not controlled by somatostatin analogues.乙基替洛曲坦用于治疗生长抑素类似物无法控制的类癌综合征腹泻。
Drugs Today (Barc). 2018 Jul;54(7):423-432. doi: 10.1358/dot.2018.54.7.2834460.
本文引用的文献
1
Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs.奥氮平口服可有效治疗类癌综合征腹泻，且对生长抑素类似物无反应。
Oncologist. 2019 Feb;24(2):255-258. doi: 10.1634/theoncologist.2018-0191. Epub 2018 Aug 31.
2
Carcinoid syndrome: update on the pathophysiology and treatment.类癌综合征：病理生理学和治疗的最新进展。
Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e490s. doi: 10.6061/clinics/2018/e490s.
3
Economic analysis of inadequate symptom control in carcinoid syndrome in the United States.美国类癌综合征症状控制不足的经济分析。
Future Oncol. 2018 Oct;14(23):2361-2370. doi: 10.2217/fon-2018-0129. Epub 2018 Aug 10.
4
Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective.泰罗替坦乙酯治疗类癌综合征腹泻的预算影响：美国健康计划视角。
Clin Ther. 2017 Dec;39(12):2338-2344. doi: 10.1016/j.clinthera.2017.10.019. Epub 2017 Nov 23.
5
Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.理解类癌综合征患者体验：替利曲塞乙酯随机、安慰剂对照研究的退出访谈。
Clin Ther. 2017 Nov;39(11):2158-2168. doi: 10.1016/j.clinthera.2017.09.013. Epub 2017 Oct 23.
6
7
Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs.用生长抑素类似物治疗控制不佳的类癌综合征腹泻时，使用乙基替加色罗的成本效益分析。
J Med Econ. 2018 Feb;21(2):182-188. doi: 10.1080/13696998.2017.1387120. Epub 2017 Oct 9.
8
Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs.患者报告的神经内分泌肿瘤（NET）诊断负担：NET患者首次全球调查结果
J Glob Oncol. 2016 Jun 8;3(1):43-53. doi: 10.1200/JGO.2015.002980. eCollection 2017 Feb.
9
Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients.类癌综合征与老年患者神经内分泌肿瘤诊断后第一年的治疗费用。
Oncologist. 2017 Dec;22(12):1451-1462. doi: 10.1634/theoncologist.2017-0149. Epub 2017 Jun 22.
10
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.北美神经内分泌肿瘤学会关于中肠神经内分泌肿瘤监测与医学管理的共识指南
Pancreas. 2017 Jul;46(6):707-714. doi: 10.1097/MPA.0000000000000850.
Zotero 插件